Molecule News and Research

RSS

Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells

Many marine natural products show anticancer activity, but some can reverse multidrug resistance in cancer cells. A new investigation by Robert J. Capon of the University of Queensland correlates the products' structures with their activity.

12 Apr 2012

New compound reverses major symptoms associated with FXS

A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.

12 Apr 2012

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

12 Apr 2012

Spider venom studied as treatment for breast cancer

James Cook University Professor Norelle Daly has received a $205,000 research grant from the National Breast Cancer Foundation to analyze whether the venom of tarantulas and funnel web spiders can kill breast cancer cells.

10 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Researchers discover two molecules that control liver glucose production

In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose---- the simple sugar that is the source of energy in human cells and the central player in diabetes.

9 Apr 2012

C8 MediSensors seeks CE Mark Approval for Optical Glucose Monitor

C8 MediSensors, Inc., the leader in developing non-invasive continuous glucose monitoring for people with diabetes, announced today that it has filed for CE mark approval to market the C8 MediSensors Optical Glucose Monitor in Europe. The monitor is currently an adjunct investigational device.

7 Apr 2012

NIMH honors SUNY Downstate professor with MERIT award

Todd C. Sacktor, M.D., distinguished professor of physiology and pharmacology and of neurology at SUNY Downstate Medical Center, has received a MERIT (Method to Extend Research in Time) award from the National Institute of Mental Health (NIMH) for his research on memory.

7 Apr 2012

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

5 Apr 2012

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

In collaboration with a Brussels University team under the leadership of Nick Devoogdt and a French team from INSERM, Serge Muyldermans and his team, associated with VIB and Vrije Universiteit Brussel, have succeeded in developing the first patient-friendly, non-invasive method for differentiating dangerous strictures in blood vessels, so-called vulnerable atherosclerotic plaques, from less dangerous ones.

5 Apr 2012

UV light-activated on-off switch for Morpholinos

University of Oregon scientists collaborating with an Oregon company that synthesizes antisense Morpholinos for genetic research have developed a UV light-activated on-off switch for the vital gene-blocking molecule. Based on initial testing in zebra-fish embryos, the enhanced molecule promises to deliver new insights for developmental biologists and brain researchers.

5 Apr 2012

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.

5 Apr 2012

Scripps Florida scientists to create new screening tests for HCV treatment discovery

Scientists from the Florida campus of The Scripps Research Institute have been awarded just over $1 million from the National Institutes of Health for a three-year study to develop new high-throughput screening tests to find compounds that disable a protein essential to hepatitis C virus (HCV) replication.

5 Apr 2012

Reactivation of p53 may be a highly selective treatment modality for virally-induced lymphoma

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

4 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Gbb38 protein helps explain how cells send many long-haul messages

As they work together to form body parts, cells in developing organisms communicate like workers at a construction site. The discovery of a new signaling molecule in flies by Brown University biologists not only helps explain how cells send many long-haul messages, but also provides new clues for researchers who study how human development goes awry, for instance in cases of cleft lip and palate.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

Molecule News and Research

Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells

New compound reverses major symptoms associated with FXS

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

Spider venom studied as treatment for breast cancer

Soon a vaccine that targets 90% of all cancers

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Researchers discover two molecules that control liver glucose production

C8 MediSensors seeks CE Mark Approval for Optical Glucose Monitor

NIMH honors SUNY Downstate professor with MERIT award

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

UV light-activated on-off switch for Morpholinos

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Scripps Florida scientists to create new screening tests for HCV treatment discovery

Reactivation of p53 may be a highly selective treatment modality for virally-induced lymphoma

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Lilly announces results of three preclinical studies that focus on c-MET receptor

Gbb38 protein helps explain how cells send many long-haul messages

TLR4/MD-2 protein complex triggers morphine-induced inflammation

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News